Key result
Statin therapy in patients with calcific aortic valve disease resulted in a 5% change in aortic valve area compared to 15% in nontreated patients (p=0.579), despite significant LDL lowering.
Why the study?
Does statin therapy reduce the progression of aortic valve area reduction in patients with calcific aortic valve disease?
Does statin therapy reduce the progression of aortic valve area reduction in patients with calcific aortic valve disease?
Applying the LDL-density-radius theory to combined data from SALTIRE and RAAVE suggests that statin-induced LDL lowering is associated with reduced progression of aortic valve area narrowing in calcific aortic valve disease.
SALTIRE and RAAVE were the first two studies to evaluate the use of statin therapy for impeding calcific aortic valve disease (CAVD). This review presents the findings of low-density lipoprotein (LDL)-density-radius theory as tested using the combined results from the SALTIRE and RAAVE studies. Patients who received statin therapy had a greater degree of LDL cholesterol lowering, seen as the % change in LDL (47 vs 2%, p = 0.012), which in itself was significantly associated with a lesser change in aortic valve area (AVA; p < 0.001 and R(2) = 0.27). The percent change in the AVA for the treated patients was 5% and 15% for the nontreated patients (p = 0.579 and R(2) = 0.03). In summary, these published findings suggest that when applying the LDL-density-radius theory, which combines the cellular biology and the hemodynamics as defined by the continuity equation for AVA, there may be a role for lipid-lowering therapy in contemporary patients with calcific aortic valve disease (CAVD).
No takes yet. Share an insight, caveat, or question.
Rajamannan et al. (2015) conducted a review in Calcific aortic valve disease (CAVD). Statin therapy vs. Nontreated patients was evaluated on Percent change in aortic valve area (AVA) (p=0.579). Statin therapy in patients with calcific aortic valve disease resulted in a 5% change in aortic valve area compared to 15% in nontreated patients (p=0.579), despite significant LDL lowering.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Statin therapyMore from Expert Review of Cardiovascular Therapy